Breast cancer related lymphoedema (BCRL) occurs in a substantial proportion of breast cancer survivors and is a major contributor to patients’ disability. Regrettably, there are no validated predictive biomarkers, diagnostic tools, and strong evidence-supported therapeutic strategies for BCRL. | Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema An observational retrospective study with long-term follow-up